SecBot SecBot
SECBOTREPLAY Home › Report › SABS

SABS · SAB Biotherapeutics announced upcoming data presentations at the ADA…

SAB Biotherapeutics, Inc. · PRESS-RELEASE filed May 29, 2026 at 08:00 ET

At the news

NEUTRALIMPACT 3/10

PRESS-RELEASE filed May 29, 2026 at 08:00 ET

SAB Biotherapeutics announced upcoming data presentations at the ADA and FOCIS conferences in June 2026, highlighting its lead program SAB-142 for type 1 diabetes. The press release contains no new clinical data, financial results, or regulatory milestones, it is a routine conference participation announcement with no material impact on the company's valuation.

  • SAB BIO will present an oral presentation at ADA 2026 (June 5-8) and a poster at FOCIS 2026 (June 9-12).
  • Presentations focus on SAB-142, a fully human anti-thymocyte immunoglobulin for Stage 3 type 1 diabetes.
  • Topline data readout for the registrational Phase 2b SAFEGUARD study expected in 2H 2027.
  • No new clinical data, financial figures, or regulatory decisions were disclosed in this press release.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access